ADIAL PHARMACEUTICALS, INC.
No enriched coverage for $ADIL in the last 7 days.
No SEC Form 4 filings for $ADIL in the last 30 days.
See all $ADIL insider activity →Adial Pharmaceuticals (ADIL) adjourned votes on Proposals 3–6 during its 2026 Annual Meeting, awaiting Nasdaq approval. The meeting will reconvene Oct. 26. Proposals 1,2,7-12 were voted on Sept. 17. The record date remains Aug. 17.
ADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events As previously disclosed in that Current Report on Form 8-K filed by Adial Pharmaceuticals, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on September 18, 2026, on September 17, 2026, the Company convened its 2026 Annual Meetin
Adial Pharmaceuticals (NASDAQ:ADIL) appointed David Rubenstein, M.D., Ph.D. as Chief Scientist to lead research and development of AT177, a treatment for ulcerative colitis. Rubenstein previously led the FDA approval of tapinarof at Dermavant Sciences. AT177 is expected to begin first-in-human trials in 2027, according to the company.
Recent ADIL coverage spans corporate actions, financial news and earnings.
The delay adds uncertainty to the listing process and may pressure the stock lower until Nasdaq approval is secured.
Near-term trading risk centers on whether Nasdaq approval arrives before the next reconvened vote date.
The hire may improve confidence in the company's ulcerative colitis program and could support the stock.
The adjourned vote reflects ongoing regulatory uncertainty, likely keeping the stock flat until Nasdaq approval is resolved.
The approvals may dilute existing shareholders but provide additional equity compensation tools and increase share count for future financing.
AlphAI scores every news story that mentions ADIL with an AI model for sentiment and relevance, and aggregates insider trades from ADIAL PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Adial Pharmaceuticals (ADIL) adjourned votes on Proposals 3–6 during its 2026 Annual Meeting, awaiting Nasdaq approval. The meeting will reconvene Oct. 26. Proposals 1,2,7-12 were voted on Sept. 17. The record date remains Aug. 17.
1 min readADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events As previously disclosed in that Current Report on Form 8-K filed by Adial Pharmaceuticals, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on September 18, 2026, on September 17, 2026, the Company convened its 2026 Annual Meetin
3 min readAdial Pharmaceuticals (NASDAQ:ADIL) appointed David Rubenstein, M.D., Ph.D. as Chief Scientist to lead research and development of AT177, a treatment for ulcerative colitis. Rubenstein previously led the FDA approval of tapinarof at Dermavant Sciences. AT177 is expected to begin first-in-human trials in 2027, according to the company.
1 min readAdial Pharmaceuticals (ADIL) adjourned votes on four proposals pending Nasdaq listing approval. The company held its 2026 Annual Meeting on Sept 17, voting on some proposals but delaying others. Votes on Proposals 3–6 were adjourned to Oct 1, then further delayed to Oct 15, 2026, due to outstanding Nasdaq approval. Shareholders who submitted proxies need not act unless changing their vote.
1 min readADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 17, 2026, Adial Pharmaceuticals, Inc. (the “Company”) convened its 2026 Annual Meeting of Stockholders (the “
1 min readADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 ADIAL PHARMACEUTICALS, INC. UNAUDITED PRO FORMA CONDENSED FINANCIAL INFORMATION The following unaudited pro forma condensed financial information presents the historical unaudited consolidated balance sheet as of June 30, 2026 of Adial Pharmaceuticals, Inc. (“Adial”
2 min readADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. On August 19, 2026, Adial Pharmaceuticals, Inc. (the “Company”) granted an option to purchase 307,814 shares of Company common stock to an individual as a material inducement to such person becoming an employee of the Company. Th
1 min readAdial Pharmaceuticals (ADIL) reported Q2 2026 results ended June 30, 2026, including a Q2 net loss of $52.0M ($11.25/share) versus $2.0M in Q2 2025. Cash was $28.7M. The company completed the first $32M tranche of a $64M private placement and acquired Azora Therapeutics, adding AT177 for ulcerative colitis. ADIL stock fell to $3.98.
4 min readADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Adiel Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update Completed acquisition of Azora Therapeutics, adding AT177, a fully synthetic, oral, colon-targeted aryl hydrocarbon receptor (“Ahr”) agonist in development for ulcerative
2 min readADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As of August 10, 2026, Adial Pharmaceuticals, Inc. (the “Company”) anticipates that the employment of its current President
3 min read
